TARA vs. ACHL, INKT, SRZN, PLUR, NKGN, ESLA, SABS, CRTX, QNCX, and BCLI
Should you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Achilles Therapeutics (ACHL), MiNK Therapeutics (INKT), Surrozen (SRZN), Pluri (PLUR), NKGen Biotech (NKGN), Estrella Immunopharma (ESLA), SAB Biotherapeutics (SABS), Cortexyme (CRTX), Quince Therapeutics (QNCX), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "medical" sector.
Achilles Therapeutics (NASDAQ:ACHL) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability.
Protara Therapeutics' return on equity of -42.95% beat Achilles Therapeutics' return on equity.
In the previous week, Protara Therapeutics had 4 more articles in the media than Achilles Therapeutics. MarketBeat recorded 10 mentions for Protara Therapeutics and 6 mentions for Achilles Therapeutics. Protara Therapeutics' average media sentiment score of 1.18 beat Achilles Therapeutics' score of -0.12 indicating that Achilles Therapeutics is being referred to more favorably in the media.
56.4% of Achilles Therapeutics shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by insiders. Comparatively, 18.4% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Achilles Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 334.59%. Protara Therapeutics has a consensus target price of $26.50, indicating a potential upside of 665.90%. Given Achilles Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protara Therapeutics is more favorable than Achilles Therapeutics.
Protara Therapeutics received 14 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. Likewise, 63.27% of users gave Protara Therapeutics an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote.
Achilles Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500.
Protara Therapeutics is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Protara Therapeutics beats Achilles Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Protara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protara Therapeutics Competitors List
Related Companies and Tools
